PT  - JOURNAL ARTICLE
AU  - Savin, M.J.
AU  - Wang, H.
AU  - Pei, H.
AU  - Aiello, A.E.
AU  - Assuras, S.
AU  - Caspi, A.
AU  - Moffitt, T.E.
AU  - Muenning, P.A.
AU  - Ryan, C.P.
AU  - Shi, B.
AU  - Stern, Y.
AU  - Sugden, K.
AU  - Valeri, L.
AU  - Belsky, D.W.
TI  - Association of a pace of aging epigenetic clock with rate of cognitive decline in the Framingham Heart Study Offspring Cohort
AID  - 10.1101/2024.05.21.24307683
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.21.24307683
4099  - http://medrxiv.org/content/early/2024/05/21/2024.05.21.24307683.short
4100  - http://medrxiv.org/content/early/2024/05/21/2024.05.21.24307683.full
AB  - Introduction The geroscience hypothesis proposes systemic biological aging is a root cause of cognitive decline.Methods We analyzed Framingham Heart Study Offspring Cohort data (n=2,296; 46% male; baseline age M=62, SD=9, range=25-101y). We measured cognitive decline across two decades of neuropsychological-testing follow-up. We measured pace of aging using the DunedinPACE epigenetic clock. Analysis tested if participants with faster DunedinPACE values experienced more rapid preclinical cognitive decline as compared to those with slower DunedinPACE values.Results Participants with faster DunedinPACE had poorer cognitive functioning at baseline and experienced more rapid cognitive decline over follow-up. Results were robust to confounders and consistent across population strata. Findings were similar for the PhenoAge and GrimAge epigenetic clocks.Discussion Faster pace of aging is a risk factor for preclinical cognitive decline. Metrics of biological aging may inform risk stratification in clinical trials and prognosis in patient care.Competing Interest StatementDisclosures: AC, TEM, KS, and DWB are inventors of the Duke University and University of Otago Invention DunedinPACE, which is licensed to TruDiagnostic.Funding StatementAcknowledgments: DWB is a fellow of the CIFAR CBD Network. Sources of Funding: This project was supported by US National Institutes on Aging grants R01AG073402, R01AG073207. MJS is supported by a Diversity Supplement from the National Institute on Aging R01AG073402-0251. DWB is a fellow of the CIFAR CBD Network.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at Framingham Heart StudyI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors